Clinical trial
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression…
NCT00078403 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00078403 |
|---|---|
| Title | Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) |
| Official title | Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Hepatitis C, Liver Disease |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2a, Ribavirin |
| Enrollment | 333 |
| Start date | Jul 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Feb 25, 2004 |
| Last update posted | Nov 8, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: